Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
A manual for health managers
Scientific advice
Prevention and control of communicable diseases in prison settings.
Première Conférence ministérielle mondiale de l’OMS
Mettre fin à la tuberculose à l’ère du développement durable : une réponse multisectorielle
Moscou, Fédération de Russie, 16-17 novembre 2017
Public Health Situation Analysis and Interventions 10 October 2017
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Le paludisme, appelé également malaria, ou « Mal‘aria », ce qui signifie « mauvais air
», est une maladie qui menace 3 milliards de personnes dans 99 pays dans le monde.1
Les personnes les plus vulnérables sont les jeunes enfants et les femmes enceintes,
car c’est parmi cette populatio...n que le risque de décès est le plus élevé.2
Au Bénin, le paludisme représente environ 41% des motifs de recours aux soins et
première cause de consultation, d’hospitalisation et de décès parmi la population en 2012
more
The effect of music intervention on mild and moderate Intellectually
disabled children was studied in non-randomized pre-test post-test control
group design at an Indian state (Jammu) J&K
Copenhagen, Denmark, 7–8 March 2017. Meeting report
15. Euro Surveill. 2017;22(47):pii=17-00103
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more